Clinical Trials Browser

Phase 1 × ON 01910 × Clear all

NCT00861510 2019-12-03

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT00854646 2018-01-10

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Phase 1 Completed

22 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00861783 2017-06-23

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Phase 1 Completed

16 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT01165905 2017-06-23

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Phase 1 Completed

10 enrolled

Tumor-Agnostic

Neoplasms

NCT01168011 2017-06-23

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Phase 1 Completed

68 enrolled

Other solid neoplasm

Solid Tumor

NCT01538563 2017-06-23

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Phase 1 Completed

42 enrolled

Tumor-Agnostic

Neoplasms